Large gap with delayed quotes
|
Last quote
04/25/2026
-
02:00:00
|
Bid
04/27/2026 -
14:51:36
|
Bid Volume |
Ask
04/27/2026 -
14:51:36
|
Ask Volume |
|---|---|---|---|---|
|
40.94
0.00
(
0.00% )
|
40.91
|
4,000 |
40.93
|
400 |
Analysis date: 24.04.2026
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 27.02.2026.
Interest
Strong
Strong
Three stars since 31.03.2026.
Earnings Rev Trend
-0.10
-0.10
Compared to seven weeks ago, the analysts have not significantly revised their earnings per share estimates (changes between +1% and -1% are considered neutral). But the last significant trend is negative since 20.02.2026 at a price of 22.28.
Evaluation
Strongly undervalued
Strongly undervalued
Based on its growth potential and our own criteria, we believe the share price is currently undervalued.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 31.03.2026.
4wk Rel Perf
128.33%
128.33%
The four-week dividend-adjusted overperformance versus SP500 is 128.33%.
Sensibility
High
High
High, no change over 1 year.
Bear Market Factor
Middle
Middle
On average, the stock is likely to decline with the index.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 4.70%.
Mkt Cap in $bn
5.23
5.23
With a market capitalization between $2 & $8bn, APELLIS PHARMS. is considered a mid-cap stock.
G/PE Ratio
1.12
1.12
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 0.9 indicates that the stock's price presents a discount to growth of
LT P/E
24.33
24.33
The estimated PE is for the year 2029.
LT Growth
27.21%
27.21%
The annualized growth estimate is for the current year to 2029.
Avg. Nb analysts
17
17
Over the last seven weeks, an average of 17 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
303
303
For 1% of index variation, the stock varies on average by 3.03%.
Correlation
0.24
0.24
Stock movements are strongly independent of index variations.
Value at Risk
38.89
38.89
The value at risk is estimated at USD 38.89. The risk is therefore 95.00%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
22.04.2022
22.04.2022